Core Viewpoint - Ginkgo Bioworks is settling multiple derivative actions with a total payment of $4,125,000 to be made by the Individual Defendants' Insurers, which is intended to benefit the company and its shareholders [5][7][10]. Summary by Sections Settlement Details - The settlement amount of $4,125,000 will be paid to Ginkgo within 30 days after the court enters the judgment [5]. - The settlement includes all fees and expenses of Plaintiffs' Counsel and Service Awards, which will be paid if approved by the court [5][8]. - Ginkgo will terminate a specific contract and implement corporate governance reforms for at least three years as part of the settlement [6]. Court Approval - A settlement hearing is scheduled for December 18, 2025, where the court will determine the fairness and adequacy of the settlement [9][10]. - Current Ginkgo stockholders have the right to appear at the hearing and object to the settlement or fee amounts [11][12]. Governance Reforms - The Board of Ginkgo has committed to adopting and maintaining comprehensive corporate governance and internal control reforms as part of the settlement [6][7]. - The Board believes the settlement confers substantial benefits to Ginkgo and its stockholders [7]. Legal Proceedings - The derivative actions are being settled in both the Northern District of California and Delaware Chancery Court [5][10]. - The settlement is part of a broader effort to address claims asserted in the derivative actions [6].

Core Insights - Quest Diagnostics has received Breakthrough Device Designation from the FDA for its Haystack MRD® test, aimed at identifying MRD-positive patients with stage II colorectal cancer post-surgery who may benefit from adjuvant therapy [1][3] - The Haystack MRD test is supported by a growing body of research indicating its effectiveness in detecting residual or recurrent cancer from solid tumors, enhancing both clinical and pharmaceutical applications [2][4] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. [6] - The company emphasizes the importance of diagnostic insights derived from laboratory testing to improve health outcomes and empower healthcare decisions [6] Product Details - Haystack MRD is a liquid biopsy test designed to detect low levels of circulating-tumor DNA (ctDNA) in the bloodstream, which can indicate residual, recurrent, or resistant disease in cancer patients [5] - The test has been utilized in multiple clinical trials and is available for clinical use across over 75 top cancer and academic centers [5] Research and Development - The Breakthrough Devices Program aims to expedite the development and approval of medical devices that provide effective treatment or diagnosis for life-threatening conditions, which aligns with the goals of Quest Diagnostics in advancing the Haystack MRD test [3] - A recent survey indicated that 96% of oncologists believe MRD testing can identify cancer recurrence earlier than current methods, highlighting the test's potential impact on clinical practices [4]

Core Insights - Ginkgo Bioworks has formed a strategic partnership with Inductive Bio and Tangible Scientific to enhance AI-driven drug discovery, making it more accessible across the industry [1][2] - The collaboration integrates Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design, and Tangible Scientific's compound management platform to streamline drug discovery processes [2][3] Group 1: Partnership Objectives - The partnership aims to transition from in-silico compound designs to validated experimental results in a single digital workflow, reducing synthesis cycles and overall drug discovery costs [2][3] - By coupling model-driven design with efficient logistics, the collaboration seeks to enable scientists to iterate quickly and utilize advanced digital tools for drug discovery [4][8] Group 2: Technological Integration - Ginkgo Datapoints provides high-quality ADME profiling services, including metrics like microsomal stability and permeability, benefiting from Boston's biopharma hub logistics [5][6] - Tangible Scientific's platform facilitates secure storage and rapid movement of compounds, allowing researchers to access Ginkgo's services directly from their digital environments [6][12] Group 3: Industry Context - The drug discovery process has evolved into a complex global logistics challenge, necessitating efficient coordination among various vendors and locations [3] - The partnership aligns with the FDA's goals for faster drug development timelines and increased use of AI tools in the industry [8] Group 4: Service Availability - The integrated services are currently available for pharmaceutical and biotech teams aiming to enhance ADMET optimization and reduce iteration times [9]

The bullish case only gets stronger once investors take into account DNA's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on DNA for more gains in the near future. After reaching an important support level, Ginkgo Bioworks Holdings, Inc. (DNA) could be a good stock pick ...

Seasoned life ‑ science executive to spearhead global go ‑ to ‑ market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science ‑ driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of BrianO'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes ...

Core Viewpoint - Ginkgo Bioworks has experienced significant stock price appreciation, with shares more than doubling to over $13, attributed to favorable market conditions [1]. Company Summary - Ginkgo Bioworks is a cell programming and biosecurity company that has emerged as one of the market's biggest winners in recent months [1]. Market Context - The overall market environment has contributed positively to the performance of Ginkgo Bioworks, leading to a substantial increase in its stock value [1].

Financial Data and Key Metrics Changes - The company achieved a $250 million annual run rate cost savings target a quarter early, with cash and cash equivalents totaling $474 million and no bank debt, providing a margin of safety [5][6][78] - Total adjusted EBITDA improved to negative $28 million in 2025 from negative $99 million in 2024, representing a 72% improvement [12] - Cash burn decreased significantly from $110 million in 2024 to $38 million in 2025, attributed to restructuring efforts [13] Business Line Data and Key Metrics Changes - Cell engineering revenue reached $39 million in 2025, an 8% increase compared to 2024, with 120 revenue-generating programs, a 10% year-over-year increase [9] - Biosecurity revenue was $10 million in 2025, with a segment gross margin of 18% [10] - R&D expenses for cell engineering decreased by 63% from $84 million in 2024 to $31 million in 2025, while G&A expenses decreased by 57% from $33 million to $14 million [11] Market Data and Key Metrics Changes - The company reaffirmed its total revenue guidance for 2025, expecting between $167 million and $187 million, with cell engineering revenue projected between $117 million and $137 million, and biosecurity revenue expected to be at least $40 million [14] Company Strategy and Development Direction - The company is transitioning from an R&D solutions business to the life science tool space, focusing on automation and data points as key growth areas [4][16] - The strategic focus includes maintaining a cash margin of safety while exploring growth opportunities leading into 2026 [6][78] - The company aims to leverage its automation technology to address the demand for increased output from existing R&D resources, particularly in the context of economic pressures and competition [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of automation as a significant revenue driver, aiming to make it as general-purpose as the lab bench [81][83] - The company is exploring opportunities in the CRO services market, emphasizing the importance of automation to reduce R&D costs and improve scalability [62][64] - Management highlighted the potential for AI-enabled science and the need for investment in automated lab environments to enhance research capabilities [55][57] Other Important Information - The company launched its first reagent product, a cell-free protein synthesis kit, which has already garnered interest in the academic research market [69][75] - The company is actively engaging with customers to provide competitive pricing for CRO services, aiming to match overseas providers [96] Q&A Session Summary Question: Is Ginkgo Automation expected to become a primary driver of revenue? - Management indicated that automation is anticipated to be a significant part of future business, potentially becoming the majority of revenue if successful in making it as general as the lab bench [81][83] Question: Are there plans for acquisitions? - Currently, there are no immediate acquisition plans, but the company remains open to opportunities if they align well with strategic goals [84] Question: Can you elaborate on Ginkgo RNA solutions? - RNA solutions are being developed as a service based on expertise in RNA discovery, with the potential for more offerings in the future [86][88] Question: Can you provide more details on AdMe data generation software? - Management discussed the potential for developing AI models based on generated AdMe data, emphasizing the importance of providing competitive pricing for CRO services [91][97]

Financial Performance & Targets - Ginkgo achieved its target of $250 million in annualized run-rate cost savings from Q1 2024 to Q2 2025[13, 50] - Ginkgo's Q2 2025 Cell Engineering revenue was $39 million, an 8% increase year-over-year[34] - Biosecurity revenue for Q2 2025 was $10 million, a 48% decrease year-over-year[34] - The company reaffirms its total revenue guidance for FY2025, projecting $167-$187 million, including $117-137 million from Cell Engineering and $40+ million from Biosecurity[37, 52] - Ginkgo aims to reach Adjusted EBITDA breakeven by the end of 2026[11, 46, 53] - Ginkgo had $474 million in cash, cash equivalents, and marketable securities with no bank debt[15, 16] Strategic Initiatives - Ginkgo is expanding from its Solutions business into tools, launching its first direct-to-scientist product: a cell-free protein synthesis system[11, 43, 63] - Ginkgo's Automation and Datapoints are establishing themselves as critical tools in AI-enabled science[43, 143] - Ginkgo has sampled flights originating from 128 countries, representing 65% of nations globally[33]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 _______________________ ...

Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2025 Financial Results Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Mass – August 7, 2025 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the ...